Superbug surveillance: 14,000 patients swabbed to map resistance

NCT ID NCT04937361

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study monitored over 14,000 hospital patients for multidrug-resistant organisms (MDROs) by taking rectal swabs and tracking bloodstream infections. Researchers analyzed the bacteria's genetics and how they resist antibiotics, aiming to understand how resistance emerges and spreads. The study also looked at how COVID-19 infection control measures affected hospital-acquired infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could help hospitals better track and control the spread of drug-resistant bacteria, improving infection prevention strategies.

What could go wrong

This is an observational study, not a treatment trial. It does not test any new drug or intervention, so it cannot directly lead to a cure or therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MDRO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multidrug-resistant tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Klinik für Infektiologie und Mikrobiologie

    Lübeck, Germany